Welcome to NanoViricide's Investor Relations section.
NanoViricides, Inc. is a leading company in the application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology permits direct attacks at multiple points on a virus particle. It is believed that such actions lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.
We have been aggressively expanding our portfolio of virus targets and drug candidates every year since our inception in May, 2005.
"PENICILLIN" FOR VIRUSES
Eradicating Diseases Caused by Viruses Using 21st Century Nanotechnology
Presented by: Eugene Seymour, MD, MPH
Chief Executive Officer
December - 2017
November 6, 2017 - NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
October 17, 2017 - NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology
- 04-15-2014 NanoViricides won the IAIR AWARD
- NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
- 02-20-2014Dr. Anil R. Diwan Recognized as "Researcher of the year".
- NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as "Researcher of the Year" by BusinessNewHaven, a Connecticut Area Business Journal.
1 Controls Drive,
Shelton, CT 06484